Innate Pharma
Research Innate Pharma (IPHA) on Bullrun: market cap USD 152.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIPHA
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 152.12M
- Financial periodQ2 2026
Valuation Snapshot
latest market cap is USD 152.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 2.79M | -EUR 49.18M | -EUR 34.91M | -1242.2% | -0.55 | EUR 28.09M | EUR 22.57M | -EUR 21.70M |
| FY2024 | EUR 12.62M | -EUR 49.47M | -EUR 7.29M | -252.4% | -0.61 | EUR 66.40M | EUR 31.00M | EUR 8.83M |
| FY2023 | EUR 51.90M | -EUR 7.57M | -EUR 52.90M | 10.8% | -0.09 | EUR 70.61M | EUR 39.89M | EUR 51.90M |
| FY2022 | EUR 49.58M | -EUR 58.10M | -EUR 20.28M | 12.1% | -0.73 | EUR 84.23M | EUR 42.25M | EUR 54.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 152.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 163.98M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 154.21M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 225.76M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 299.19M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 362.71M | n/a | n/a | n/a |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Innate Pharma's market cap?
Innate Pharma's market capitalization is USD 152.12M.
What does Innate Pharma do?
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.